司吗酮 | 88939-40-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 中文名称: 司吗酮
• 英文名称: Semorphone
• 英文别名: (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-(2-methoxyethyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
• CAS: 88939-40-6
• 化学式: C₁₉H₂₃NO₅
• 分子量: 345.4
• InChiKey: PBGIBLLOMGURPS-GRGSLBFTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  79.2
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE
  申请人：Waterville Valley Technologies, Inc.

  公开号：US20160326182A1

  公开（公告）日：2016-11-10

  Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.

  提供了耐滥用的阿片类化合物、药物输送系统、含有阿片类药物与化学基团共价结合的制药组合物。还提供了将活性成分输送给受试者的方法以及预防阿片类药物滥用的方法。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN AND DEPENDANCE DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA DOULEUR ET DE TROUBLES DE LA DÉPENDANCE
  申请人：RIPPLE THERAPEUTICS CORP

  公开号：WO2021024039A1

  公开（公告）日：2021-02-11

  Provided herein are (e.g., controlled release) compositions for the treatment of acute or chronic diseases or disorders. Described herein are processable opioid conjugates. Also described herein are compositions and methods for the treatment of central nervous system (CNS) diseases or disorders including chronic pain (e.g., cancer pain), acute pain, opioid addiction, alcohol addiction, alcohol dependence, opioid-induced constipation, and narcotic depression. Said compositions and methods comprise opioid agonists and/or opioid antagonists, which demonstrate CNS activity and/or other desirable activities. Injection of said compositions subcutaneously or intraspinally provides therapeutic benefit to individuals suffering from CNS diseases or disorders

  本文提供了用于治疗急性或慢性疾病或障碍的（例如，控释）组合物。本文描述了可加工的阿片类结合物。本文还描述了用于治疗中枢神经系统（CNS）疾病或障碍的组合物和方法，包括慢性疼痛（例如，癌症疼痛）、急性疼痛、阿片类成瘾、酒精成瘾、酒精依赖、阿片类引起的便秘和麻醉性抑郁症。所述组合物和方法包括表现出CNS活性和/或其他理想活性的阿片类激动剂和/或阿片类拮抗剂。将所述组合物皮下或脊髓内注射可为患有中枢神经系统疾病或障碍的个体提供治疗益处。
• PROCESS FOR THE PREPARATION OF MORPHINE ANALOGUES
  申请人：Patel Nileshkumar Sureshbhai

  公开号：US20110152527A1

  公开（公告）日：2011-06-23

  The present invention relates to an improved process for preparing morphinane analogues of formula (1) wherein the substituents R 1 , R 2 , R 2a , R 3 , R 4 , R 5 and Y have the meanings as defined in the specifications.

  本发明涉及一种改进的制备公式（1）中吗啡烷类似物的过程，其中取代基R1、R2、R2a、R3、R4、R5和Y的含义如规范中定义。
• PROCESS FOR THE PREPARATION OF MORPHINANE ANALOGUES
  申请人：Sun Pharmaceutical Industries Ltd.

  公开号：US20140031550A1

  公开（公告）日：2014-01-30

  The present invention relates to an improved process for preparing morphinane analogues of formula 1 wherein the substituents R 1 , R 2 , R 2a , R 3 , R 4 , R 5 and Y have the meanings as defined in the specifications.

  本发明涉及一种改进的制备公式1的吗啡烷类似物的过程，其中取代基R1、R2、R2a、R3、R4、R5和Y的含义如规范中所定义。
• ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION
  申请人：G.L. Pharma GmbH

  公开号：EP3210596A1

  公开（公告）日：2017-08-30

  Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.

  本发明公开了一种抑制滥用的药物组合物，该药物组合物包含具有酶反应官能团的药物（其中该药物具有滥用潜力）和能够与酶反应官能团发生反应的酶（药物加工酶），其中具有酶反应官能团的药物以贮存稳定、酶反应状态包含在药物组合物中，并且在没有酶活性作用于该药物的条件下。